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Selective whole genome 
amplification of Plasmodium 
malariae DNA from clinical samples 
reveals insights into population 
structure
Amy Ibrahim1, Ernest Diez Benavente1, Debbie Nolder1,2, Stephane Proux3, 
Matthew Higgins1, Julian Muwanguzi1,2, Paula Josefina Gomez Gonzalez1, 
Hans‑Peter Fuehrer4, Cally Roper1, Francois Nosten3,5, Colin Sutherland1, Taane G. Clark1,6 & 
Susana Campino1,7*
The genomic diversity of Plasmodium malariae malaria parasites is understudied, partly because 
infected individuals tend to present with low parasite densities, leading to difficulties in obtaining 
sufficient parasite DNA for genome analysis. Selective whole genome amplification (SWGA) increases 
the relative levels of pathogen DNA in a clinical sample, but has not been adapted for P. malariae 
parasites. Here we design customized SWGA primers which successfully amplify P. malariae DnA 
extracted directly from unprocessed clinical blood samples obtained from patients with P. malariae‑
mono‑infections from six countries, and further test the efficacy of SWGA on mixed infections with 
other Plasmodium spp. SWGA enables the successful whole genome sequencing of samples with 
low parasite density (i.e. one sample with a parasitaemia of 0.0064% resulted in 44% of the genome 
covered by ≥ 5 reads), leading to an average 14‑fold increase in genome coverage when compared 
to unamplified samples. We identify a total of 868,476 genome‑wide SNPs, of which 194,709 are 
unique across 18 high‑quality isolates. After exclusion of the hypervariable subtelomeric regions, a 
high‑quality core subset of 29,899 unique SNPs is defined. Population genetic analysis suggests that 
P. malariae parasites display clear geographical separation by continent. Further, SWGA successfully 
amplifies genetic regions of interest such as orthologs of P. falciparum drug resistance‑associated 
loci (Pfdhfr, Pfdhps, Pfcrt, Pfk13 and Pfmdr1), and several non‑synonymous SNPs were detected 
in these genes. In conclusion, we have established a robust SWGA approach that can assist whole 
genome sequencing of P. malariae, and thereby facilitate the implementation of much‑needed large‑
scale multi‑population genomic studies of this neglected malaria parasite. As demonstrated in other 
Plasmodia, such genetic diversity studies can provide insights into the biology underlying the disease 
and inform malaria surveillance and control measures.
Malaria, a mosquito-borne disease caused by Plasmodium parasites, is a continuing threat to global health. There 
were an estimated 228 million cases and 405,000 deaths in  20181. The majority of mortality events are due to P. 
falciparum malaria and therefore disease control and elimination efforts have primarily targeted this species. 
open
1Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK. 2Public 
Health England (PHE) Malaria Reference Laboratory, London School of Hygiene and Tropical Medicine, London, 
UK. 3Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, 
Mahidol University, Mae Sot, Thailand. 4Department of Pathobiology, Institute of Parasitology, University of 
Veterinary Medicine, Vienna, Austria. 5Centre for Tropical Medicine and Global Health, Nuffield Department of 
Medicine, University of Oxford, Oxford, UK. 6Faculty of Epidemiology and Population Health, London School of 
Hygiene and Tropical Medicine, London, UK. 7Department of Infection Biology, London School of Hygiene and 
Tropical Medicine, London, UK. *email: Susana.campino@lshtm.ac.uk
2
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:10832  | https://doi.org/10.1038/s41598-020-67568-4
www.nature.com/scientificreports/
Molecular surveillance has demonstrated that non-falciparum malaria has been underestimated by microscopy 
 diagnosis2–5, and rapid diagnostic tests (RDT), which are unable to diagnose non-falciparum malaria to the 
species  level6,7. Molecular studies are beginning to demonstrate alarmingly high levels (4–24%) of P. malariae 
mono- and co-infections across  continents2,8–12.
P. malariae infections commonly present with mild or no symptoms, however, severe disease, including 
anaemia, renal pathologies, and  splenomegaly13–17 can occur, complications which can prove  fatal16. P. malariae 
infections present with quartan fevers with parasites that can remain in the host for  decades13,18,19 . This per-
sistence is a threat to disease elimination  strategies19. Severe P. malariae infections are commonly treated with 
an Artemisinin Combination Therapy (ACT), similar to P. falciparum infections in the same  region18. The high 
prevalence of mixed infections with P. falciparum and P. vivax means that populations of P. malariae may have 
been experiencing substantial drug pressure. Several reports have described P. malariae parasites that have not 
been cleared after treatment with standard  antimalarials8,17,20 or have initiated successful infections despite effec-
tive  chemoprophylaxis21, leading to fears of reduced drug efficacy.
Advances in whole genome sequencing (WGS) technologies now allow for large scale genome diversity 
studies. Such studies in P. falciparum and P. vivax have provided significant new understanding of the structure 
of parasite populations, intra- and inter-population genomic diversity, and identified genomic regions under 
selective pressure, such as drug resistance associated  genes22–25. However, to date only a few complete genomes 
have been assembled for P. malariae (n = 5; genome size 31.9 Mb)26,27, which have led to insights into genome 
structure including species-specific gene expansions, causing the characteristically large genome of P. malariae27. 
One expansion of note is a family encoding transmembrane domain proteins, known as Pm-fam, containing 
fam-m and fam-l genes, which are hypothesised to be involved in host–pathogen interactions and are unique 
to P. malariae  parasites26,27. To date, investigations of P. malariae genetic diversity have used microsatellite data 
and demonstrated considerable levels of genetic diversity and differences between and within populations from 
different  countries28,29. However, microsatellite markers reflect only a minority of the genome (< 0.1%), and 
further investigation using WGS data is needed to explore genetic diversity and population structure across 
endemic regions.
A major challenge in performing WGS studies using clinical parasite isolates is the difficulty in obtaining 
sufficient Plasmodium DNA from infected individuals. This is due to low parasite densities and the presence 
of human DNA from host lymphocytes and other circulating nucleated cells. For P. malariae, genome studies 
are further complicated by the lack of an in vitro culture method for this parasite species. Until now, WGS data 
for Plasmodium parasites has been obtained using DNA extracted from venous blood of clinical cases that 
were pre-filtered to remove human leukocytes, in order to reduce the amount of co-extracted human  DNA30. 
This methodology is efficient when parasite densities are high, however, this is not the case for the majority of 
P. malariae infections, particularly asymptomatic individuals, where this approach would not yield sufficient 
parasite DNA for WGS. Recently, a selective whole genome amplification (SWGA) strategy has been used to 
successfully sequence P. falciparum, P. vivax and P. knowlesi genomes from non-filtered blood and from dried 
blood spots of clinical  samples31–33. The SWGA method uses oligonucleotide primers that preferentially bind with 
high frequency to the pathogen DNA, and rarely bind to the host  genome34. The high fidelity Phi29 polymerase, 
which works through multiple displacement amplification (MDA), is used to amplify large segments (~ 70 kb) 
of DNA, primed by the SWGA oligonucleotides.
The unique but poorly understood characteristics of the P. malariae parasite, and the threat of unpredictable 
drug resistance, indicate a need for better understanding of the biological features of this neglected species. 
Knowledge of the complexity and variability of the P. malariae genome, and comparative studies with the well 
characterised P. falciparum and P. vivax  genomes23–25, could provide insights into the biology of this human 
parasite species. Here, we adapt and validate the SWGA approach for amplification of the P. malariae genome, 
successfully processing and sequencing 19 clinical samples. After selecting 18 high quality samples, we dem-
onstrate that the resulting WGS data can be used to assess genetic diversity in P. malariae genes orthologous to 
known drug resistance markers in other species, and to inform population structure. In doing so, we provide 
proof-of-principle for large-scale WGS studies using blood samples collected from malaria endemic regions to 
inform malaria control efforts, and provide new molecular information for development of diagnostics, vac-
cines and drugs.
Results
SWGA enriches P. malariae DNA and increases WGS data coverage. We performed SWGA using 
a designed primer set (denoted as Pmset1) consisting of five primers (see S1 Table) that preferentially bind the 
P. malariae genome (average binding sites located once every 2.9 kb within the P. malariae genome, compared 
to once every 45.1 kb in the human genome). For successful selective amplification it is essential that the bind-
ing sites are in close proximity in the parasite genome and spaced further apart in the human  genome35. Using 
two test samples (PM_THA_001 and PM_THA_002), we demonstrate that Pmset1 successfully amplifies the P. 
malariae genome, allowing for higher quality WGS data in comparison to non-amplification (S1 Fig.). Whilst all 
four samples were sequenced at a similar depth, we observed that amplified samples have a significant increase in 
coverage, with a mean 18.6-fold increase in the percentage of the genome covered with ≥ 5 reads when compared 
to non-amplification (S2 Table). The increase in genome coverage seen with SWGA allows for greater detection 
of SNPs which can be used for downstream population genetics analysis. As a result, there was an 800- to 13,000-
fold increase in the number of callable SNPs detected in samples amplified using Pmset1 (S2 Table).
After validation of Pmset1, 17 additional clinical samples were amplified using Pmset1 and underwent 
WGS. One sample (PM_THA_009), with a low parasitaemia of 0.0016% presented with low coverage after the 
first sequencing run (27% genome covered ≥ 5 reads), this sample was re-sequenced, and the second run had 
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better results (44% genome covered ≥ 5 reads) (S2 Table). The two sequencing runs were combined to generate 
PM_THA_009com (52% genome covered ≥ 5 reads). Excluding the separate runs for PM_THA_009, and one 
sample with low genome coverage (PM_LBR_003), the remaining samples had an average of 67.4% (± 15%) of 
the genome covered by ≥ 5 reads (S2 Table). The coverage profile after amplification was uneven, as reported for 
other  Plasmodia32, but generally, across all chromosomes, reaching coverage above the recommended cut off 
point for SNP calling (five reads or above) (Fig. 1). Coverage of the mitochondria was variable but consistently 
high in comparison to other chromosomes (mean: 26-fold coverage). The average chromosomal coverage of the 
two unamplified samples was much lower, with only 0.82% of the genome with a coverage ≥ 5 reads (S2 Fig).
SWGA is dependent on the initial parasitaemia of a sample. To determine a potential limit of para-
sitaemia for WGS, a measure of genomic coverage was assessed in nine Thailand samples for which parasitaemia 
data was available (range of parasitaemia: 0.0004% to 0.2024%). We determine a parasitaemia limit using both 
microscopy estimates and cycle threshold (CT) values calculated using the qPCR  method36. We plotted the CT 
values of each sample alongside the percentage of the genome that was covered by ≥ 5 reads. We determined that 
a CT value of 30 will lead to an estimate of 50% of the genome covered by ≥ 5 reads (Fig. 2a). Coverage results 
are unpredictable below this limit, however, as with PM_THA_001, sequence data may be usable below this 
limit. When using percentage parasitaemia, we verified that all sequence data from parasite densities higher than 
0.01% (400 parasites/ul) led to > 50% of the genome covered by five or more reads; this is a lower limit than previ-
ously defined for P. falciparum, and P. knowlesi32,37 (Fig. 2b). For difficult samples with lower parasitaemia it is 
possible to improve genome coverage by performing independent SWGA reactions and by increasing sequence 
data, as observed previously for P. vivax31, and also demonstrated here for PM_THA_009, for which merging 
data lead to > 50% of genome covered with at least 5 reads (S2 Table).
Determining and excluding hypervariable regions. Many Plasmodium species are known to contain 
large regions of repetitive sequences within the subtelomeres, which is exaggerated in the case of P. malariae, 
leading to an enlarged genome in comparison to other  species27. We defined the core genome by both excluding 
regions with > 2.25 SNPs on average per 5 kb window (S3 Fig.) or containing Pm-fam genes (Fig. 3, S4 Fig., core 
genome coordinates are listed in S3 Table), to leave a total core genome size of 23,960,057 bases (81% of the total 
PmUG01 reference genome).
Genetic diversity and population structure. We investigated the multiplicity of infection (MOI) in all 
samples using the core genome, initially through determining the proportion of SNPs that were heterozygous, 
alongside running estMOI38 for each sample which calculates the percentage of the genome that supports a MOI 
of 1 (S2 Table, S5 Fig.). The samples were P. malariae mono-infections, that is, where no other Plasmodium 
species were detected by qPCR. However, it is possible that > 1 clone of P malariae is present in a sample i.e. 
polyclonal. Using this sample set, three isolates displayed evidence of polyclonal infections (PM_LBR_002, PM_
UGA_007 and PM_THA_012). This observation was confirmed by assessing the minor allele frequency (MAF) 
distribution of these isolates, where they presented with a higher proportion of SNPs with a non-reference MAF 
Figure 1.  Sequencing coverage by chromosome after SWGA. The distribution of coverage for each position 
within the genome between 18 high quality samples, among the 14 nuclear chromosomes and the organellar 
apicoplast (the mitochondrial coverage plot is excluded due to high coverage). The blue horizontal line 
represents the recommended coverage cut-off point for SNP calling (≥ 5 reads).
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in the range 0.2 to 0.8 (S6 Fig.). For these three isolates only the major allele strain in each isolate was used in 
further population genetics analysis.
A total of 868,476 genome-wide SNPs were found within the 18 high quality samples (average of 48,249 SNPs 
per sample), of which 194,709 were unique. However, as with other Plasmodium spp., the subtelomeric region 
of the P. malariae genome contains large sections of repetitive DNA  sequence27. These regions are problematic 
when interpreting WGS data from short-read technologies such as Illumina as short reads are likely to be aligned 
to incorrect regions along the reference genome, leading to deceptively high coverage and number of SNPs.
After removing hypervariable regions, we analysed the core genome (see S3 Table for coordinates) of 18 sam-
ples (≥ 40% of the genome covered by ≥ 5 reads) and identified 29,899 unique SNPs (mean: 5,810 ± 2,229 SNPs per 
sample) for downstream population genetic analysis. We found that geographically proximal samples displayed 
less pairwise diversity than geographically separated samples, with parasites from Thailand appearing more 
closely related to each other than to parasites obtained from Africa. Nucleotide diversities (π) > 3 × 10−4 nucleotide 
differences per site are only seen when comparing samples between Thailand and Africa, and π < 2 × 10−4 was 
only seen when comparing samples within Thailand or Africa (S4 Table).
A maximum-likelihood tree was constructed using core genome SNP data and demonstrates clear regional 
separation of P. malariae parasites, with samples from the African continent clustering together, and indepen-
dently from samples originating in Thailand (Fig. 4).
Genetic variation in in orthologs of known P. falciparum genes associated with drug resist‑
ance. P. malariae parasites are commonly subject to antimalarial treatments, therefore we investigated the 
coverage and prevalence of mutations in orthologs of known P. falciparum genes associated with drug resist-
ance (Pfcrt, Pfdhfr, Pfdhps, Pfk13 and Pfmdr1; gene IDs are in S5 Table). SNPs were only found in Pmdhfr (n = 3; 
2 non-synonymous), Pmdhps (n = 5; 1 non-synonymous) and Pmmdr1 (n = 4, 2 non-synonymous) (Fig.  5, 
Table 1). SNPs within Pmdhfr at positions 1,292,026 and 1,292,193 in chromosome 5 appear to be more common 
globally than other SNPs, whereas SNPs within Pmdhps and Pmmdr1 appear to be more prevalent in Thailand 
than Africa (Table 2). All of the non-synonymous mutations found within Pmdhfr led to amino acid alterations 
(F57L, R58S and N114S) at positions that align with known drug-resistance associated positions within the 
Pfdhfr ortholog (C59R and S108N respectively) upon amino acid allignment (Table 1, S7 Fig.)43. In addition, 
Figure 2.  Correlation between parasite density and genome coverage. (a) Nine samples (amplified with SWGA 
approach) were used to assess the effect of parasite density (as measured by CT values obtained from qPCR) 
on the proportion of the genome covered by five or more reads. Each point demonstrates a single sample, with 
a lowess line of best fit. The dashed horizontal line represents a cut off of 50% of the genome covered by 5 or 
above, and the dashed vertical line indicates the suggested CT cut-off of 30. (b) The same plot is shown using 
parasitaemia as the measure of parasite density (percentage of RBCs parasitized). Parasitaemias range from 
0.0004% to 0.2024%, and the vertical dashed line represents the suggested parasitaemia cut-off of 0.01%.
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Figure 3.  Defining and excluding subtelomeric regions, an example with chromosome 1. The average coverage 
(pink) and number of SNPs (blue) between all 18 samples for chromosome 1. The black dashed horizontal line 
demonstrates the previously chosen SNP limit per 5 kb window (as defined in S2 Fig.). Black dashed lines are 
placed at the suggested hypervariable region cut-off points, where clusters of windows demonstrating > 2.25 
SNPs are seen. The midpoints of Pm-fam gene families are annotated; Pm-fam-l gene positions are denoted by 
a black plus, whilst Pm-fam-m gene positions are denoted with a grey circle. (S3 Fig. for all chromosomes, S3 
Table for coordinates).
Figure 4.  Population structure of P. malariae parasites. A maximum likelihood (ML) tree was generated 
using 29,899 unique SNPs from 18 amplified and sequenced samples (> 40% genome with at least fivefold 
coverage). The ML tree is unrooted and was generated using Iqtree39 with Modelfinder software used to select 
the best model of  substitution40. Horizontal branch lengths are drawn to scale demonstrating the number of 
substitutions per position, and branch bootstrap values (determined using UFBoot241) above 50 are denoted 
with a grey circle at the start of each branch. The tree was visualised in iTOL42, and branches were coloured 
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the mutation at position 527,528 within Pmmdr1 (chromosome 10), which leads to the amino acid substitution 
L1063F, aligns in close proximity to N1042D in the Pfmdr1 ortholog that is associated with quinine resistance, 
and increased mefloquine and artemisinin susceptibility (Table 1, S7 Fig.)44.  
Mixed infections. P. malariae parasites are commonly found in mixed infections with other Plasmodium 
spp.911,12. This provides a further obstacle for WGS, as not only is the human genome a potential contaminant, 
but also the other Plasmodium species present. We used four further unprocessed clinical blood samples from 
Thailand which were found to be mixed infections after  qPCR36 and underwent SWGA to determine whether 
Figure 5.  Average sequencing coverage and SNPs found within P. malariae orthologues of P. falciparum drug 
resistance associated genes. Average sequencing coverage for 18 samples across 5 genes is represented. The 
blue horizontal line indicates the coverage of 5 reads and black vertical lines are locations of SNPs (Pmdhfr: 
1,292,023, 1,292,026 and 1,292,193; Pmdhps: 1,657,704, 1,657,993, 1,658,014, 1,658,019 and 1,658,049; Pmmdr1: 
525,728, 527,072, 527,449 and 527,528).
Table 1.  Single nucleotide polymorphisms (SNPs) detected in Pmdhfr, Pmdhps and Pmmdr1 genes, and their 
downstream effects. *Amino acid alterations that lie in close proximity to known P. falciparum resistance 
mutations. SNPs leading to non-synonymous (NS) mutations are in bold, whilst intronic (I) or synonymous (S) 
mutations are unbolded.














1,292,023* C A NS ttC/ttA F57L* 0.17 G NS ttC/ttG F57L* 0.11
1,292,026* A G S agA/agG R58 0.28 C NS agA/agC R58S* 0.67
1,292,193* A G NS aAc/aGc N114S* 0.78 / / / /
Pmdhps
1,657,704 C T NS Gtg/Atg V121M 0.06 / / / /
1,657,993 C T I / / 0.28 / / / /
1,658,014 A G I / / 0.11 / / / /
1,658,019 A T I / / 0.22 C I / / 0.06
1,658,049 T A I / / 0.06 / / / /
Pmmdr1
525,728* T G NS ttA/ttC L1063F* 0.11 / / / /
527,072 C T S ttG/ttA L615 0.22 / / / /
527,449 G T NS Ctt/Att L490I 0.06 / / / /
527,528 G A S agC/agT S463 0.33 / / / /
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Pmset1 was specific to only the P. malariae genome. Each sample contained varying mixtures of other parasite 
species present and our results suggest that SWGA is likely to work if P. malariae is initially the most prevalent 
parasite in the mixed infection (i.e. has the lowest CT value) (S6 Table). However, when DNA from other species 
is present at high concentrations, SWGA may not be effective for amplification of P. malariae (S6 Table).
Discussion
P. malariae is a neglected malaria parasite with unique features, such as a longer quartan cycle and the ability to 
persist in the human host for years or  decades13. Genetic investigation of this parasite may allow us to understand 
how P. malariae is able to cause chronic infections, why there are accounts of P. malariae parasites persisting after 
treatment with ACT, and why some P. malariae infections lead to severe outcomes whilst others remain asymp-
tomatic. Malaria parasite genomics can provide important biological insights to understand this disease, but the 
difficulty of obtaining sufficient parasite DNA for WGS has been a challenge for genomic studies of P. malariae. 
Here we present the first application of SWGA for this species. We have customized the SWGA approach to suc-
cessfully amplify P. malariae DNA extracted directly from unprocessed blood from clinical samples which were 
obtained from six different countries. In agreement with  others31,32, we have demonstrated that the parasitaemia 
affects the efficiency of SWGA, and recommend using samples with a percentage parasitaemia > 0.01%, which is 
a lower threshold than reported for other  species31,32,37. The WGS data generated from SWGA-treated samples is 
of high quality with good overall coverage, leading to an average of 67.4% (± 15%) of the genome covered by ≥ 5 
reads between the 18 samples assessed in this study. Using these samples, we were able to identify 868,476 total 
SNPs (average 48,249 SNPs per sample), filtered to 104,583 total SNPs after exclusion of hypervariable regions 
(average of 5,810 SNPs per sample). This is lower than SNP prevalence documented in P. knowlesi (115,995 SNPs 
per sample including hypervariable regions)37, yet higher than SNPs found in P. vivax (14,463 SNPs per sample 
before filtering for core genome) after SWGA 31.
It is important to note that differences in the number of SNPs per sample reported could also be due to dif-
ferences in the method used for variant calling.
A maximum likelihood tree based on SNP data revealed geographic clusters, with clear separation of Afri-
can and Asian samples. This geographical clustering is consistent with data for P. falciparum45 and P. vivax 
 parasites24,45,46. Similar geographic clustering was observed in the phylogenetic analysis of SNPs in the circum-
sporozoite gene from P. malariae isolates from Africa and  Asia47. To improve geographical clustering resolution 
(i.e. by country), the number of samples investigated needs to be increased. Our data suggests that parasites 
display isolation by distance, therefore country or multi-country regional analysis of P. malariae populations 
could be used in future studies to identify regions under selection in different populations.
We further demonstrate that SWGA successfully amplifies genes orthologous to those associated with drug 
resistance in P. falciparum, and identify SNPs in Pmdhfr, Pmdhps and Pmmdr1. The effects of these SNPs are 
unknown, and to date, there are no characterised molecular markers of drug resistance in P. malariae para-
sites, even though treatment failures have been  reported19,48. Despite this, potential mutations of interest were 
Table 2.  Distribution of SNPs in Pmdhfr, Pmdhps and Pmmdr1 among 18 samples from Africa and Thailand. / 
denote Wild-type alleles (the allele observed in the PmUG01 reference genome). N denotes no coverage at this 
position. *Positions lead to amino acid substitutions that align with drug resistance-associated substitutions 
observed in P. falciparum.
Gene Pmdhfr Pmdhps Pmmdr1
Position 1292023* 1292026* 1292193* 1657704 1657993 1658014 1658019 1658049 525728 527072 527449 527528*
Reference allele C A A C C A A T T C G G
PM_THA_001 / C G / / / / / G – – –
PM_THA_002 / C G / T / / / / / / /
PM_THA_003 / C G / T A/G A/T / N N N N
PM_THA_005 / C G / T / A/T / G / / /
PM_THA_006 / C G / T A/G A/T / / N / N
PM_THA_009com / C G / / / A/C A/T / T / A
PM_THA_010 / C / / T / A/T / / T T A
PM_THA_011 / C G / / / / / / N / A
PM_THA_012 / C / / / / / / / T / A
PM_KEN_001 A G G / / / / / N / N N
PM_KEN_003 A G G / / / / / N N N –
PM_LBR_002 / C G C/T / / / / / / / A/G
PM_SDN_001 G G G / / / / / N – N N
PM_SLE_002 / C G / / / / / / T / /
PM_SLE_004 / C / / / N N N N N N N
PM_UGA_001 N N / / N N N N – – N N
PM_UGA_003 A G G / / / / / / / / A
PM_UGA_007 G G G / / / / / N N N N
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found, particularly at positions 1,292,023, 1,292,026 and 1,292,193 in chromosome 5 in the Pmdhfr gene. These 
mutations lead to amino acid substitutions F57L, R58S and N114S respectively, and align almost perfectly with 
P. falciparum amino acid substitutions C59R and S108N which are associated with reduced susceptibility to 
sulfadoxine/pyrimethamine49. The nonsynonymous mutation N114S has been previously reported in two P. 
malariae samples from Thailand and the F57L and R58L mutations have been reported in P. vivax samples from 
several geographical  regions50,51. In addition, one mutation within Pmmdr1 at position 525,728 in chromosome 
10 leads to amino acid substitution L1063F, which aligns with close proximity to N1042 in the Pfmdr1 ortholog, 
associated with reduced susceptibility to quinine and increased susceptibility to mefloquine, halofantrine and 
 artemisinin44. It is important to note that whilst treatment failures are seen with P. malariae infections, it is not 
clear whether this is due to mutations within the parasite genome leading to reduced drug efficacy, or perhaps 
a specific phenotype of this species due to the longer parasite life cycle which may reduce drug  absorption48; 
therefore further functional studies are required to determine the effect, if any, of these substitutions.
The subtelomeres, containing the fam-l and fam-m gene families are of great interest when studying P. malar-
iae, as they are unique to this species and are thought to be involved in host-parasite  interactions26. Unfortunately, 
sequence analysis of these regions is notoriously difficult using short-read technologies, therefore longer-read 
sequencing will be needed to further investigate these regions.
In conclusion, the SWGA approach offers a fast, cost effective way to explore the genome diversity of P. 
malariae from unprocessed blood of infected individuals. Further studies should consider the analysis of a larger 
number of samples from a greater geographical range and different clinical outcomes, in addition to studies 
investigating the subtelomeric regions with long read technologies. Such studies are necessary to characterize the 
epidemiology and genetic diversity of P. malariae populations, with the potential to provide biological insights 
for disease control.
Methods
Ethics statement. Isolated from Thailand were collected with ethical approval from the Mahidol Faculty 
of Tropical Medicine Ethics Committee (Ref: 2015-001.01); PHE-MRL samples are analysed under NHS Ethics 
approval (#18/LO/0738). In both instances, samples were collected according to relevant guidelines and regula-
tions in both Thailand and the UK, and informed consent was obtained for all subjects over the age of 18 (for 
subjects under 18 years old, consent was obtained from the appropriate legal guardian.
Sample collection and processing. This project used nine P. malariae DNA samples extracted from 
unprocessed venous blood from infected individuals in Thailand. Parasite density (parasites/µl) determined by 
microscopy was available for these isolates. Genomic DNA was extracted from frozen unprocessed blood using 
the QIAamp DNA Blood Mini Kit (Qiagen) or the QIAsymphony DSP DNA Kit in combination with a QIAsym-
phony SP instrument (Qiagen), according to manufacturer’s instructions. As microscopy is prone to human 
errors, all extracted DNA samples were subject to qPCR as outlined by Shokoples et al.36 to ensure that only P. 
malariae single species infections were used.
A further ten DNA samples were provided by the Public Health England-Malaria Reference Laboratory 
(PHE-MRL) at the London School of Hygiene and Tropical Medicine (LSHTM). These samples were sourced 
from individuals who had reported recent travel to only one country with malaria transmission, including: Kenya 
(n = 2), Liberia (n = 2), Sierra Leone (n = 2), Sudan (n = 1) and Uganda (n = 3) between 2010 and 2017. PHE-MRL 
samples are commonly sourced from individuals returning to visit relatives in their original native country. For 
species identification, PHE-MRL samples perform both a nested  PCR52 and  qPCR36 and are archived according 
to the species present.
Total DNA concentration for all samples was quantified using a Qubit v2.0 fluorometer (Thermo Fisher 
Scientific).
Selective whole genome amplification. The swga program (www.githu b.com/eclar ke/swga) was used 
to identify primers that preferentially amplify the P. malariae  genome35, using its reference genome (PmUG01, 
https ://plasm odb.org) as the target (foreground), and the human genome (GRCh37; https ://grch3 7.ensem 
bl.org/) as the background. The swga program ranks primers dependant on the ratio of foreground genome 
binding to the background genome binding, combined with the evenness of primer binding along the target 
genome and generates multiple potential primer sets. The five highest-ranked sets consist of combinations of 4 to 
6 oligonucleotides each, with overlapping primers. The set that ranked highest (Pmset1) consisted of five prim-
ers: TAT GTA TA*T*T, TTA TTC *G*T, TTC GTT *A*T, TTT TTA *C*G, TAT TTC *G*T, that were ordered with 
a phosphorothioate bond (represented by *) modifications to prevent primer degradation by the exonuclease 
activity of the Phi29 polymerase. To evaluate the efficacy of Pmset1 for SWGA of the P. malariae genome, we 
tested two samples (PM_THA_001 and PM_THA_002) and sequenced both before and after SWGA.
DNA samples were subject to SWGA following previously published  protocols31,32,37. All SWGA reactions 
were carried out in a UV Cabinet for PCR Operations (UV-B-AR, Grant-Bio) to eliminate potential contamina-
tion. Briefly, a maximum of 60 ng of gDNA (minimum of 5 ng) was added to a total 50 µl reaction alongside 
5 µl of 10 × Phi29 DNA Polymerase Reaction Buffer (New England BioLabs), 0.5 µl of Purified 100 × BSA (New 
England BioLabs), 0.5 µl of 250 µM Primer mix, 5 µl 10 mM dNTP (Roche), 30 units Phi29 DNA Polymerase 
(New England BioLabs) and Nuclease-Free Water (Ambion, The RNA Company) to reach a final reaction volume 
of 50 µl. The reaction was carried out on a thermocycler with the following step-down program: 5 min at 35 °C, 
10 min at 34 °C, 15 min at 33 °C, 20 min at 32 °C, 25 min 31 °C, 16 h at 30 °C and 10 min at 65 °C. After success-
ful validation of Pmset1, the remaining samples underwent SWGA as described above. After SWGA, samples 
were purified using a 1:1 ratio of AMPure XP beads (Beckman-Coulter), following manufacturer’s instructions.
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Library preparation and WGS. SWGA samples and the unamplified negative controls were sequenced 
on either an Illumina MiSeq or HiSeq4000 platform. For the MiSeq runs, the QIAseq FX DNA Library Kit 
(QIAGEN) was used for library preparation according to the manufacturer’s protocol, with a 20-min fragmenta-
tion step. For the HiSeq4000 runs, samples were prepared using the NEB Next Ultra DNA Library Prep Kit for 
Illumina (from New England BioLabs Inc., E7370). Library DNA concentration was analysed using a Qubit 2.0 
fluorometer. All sequencing reactions were performed using paired (2×) 150 bp reads.
Sequence data analysis. Raw fastq files were trimmed using trimmomatic set to default  parameters53, and 
aligned to the P. malariae UG01 reference genome (PlasmoDB) using bwa-mem  software54. SNPs were identi-
fied using the samtools software suite (samtools.sourceforge.net)55 and filtered for quality based on previously 
described  methods56. The coverage of each nucleotide position was analysed using sambamba57, which was set 
to include only SNPs with coverage levels of at least fivefold. Poor quality samples were removed (< 40% of the 
genome covered by 5 reads) to leave 18 high quality samples. We used  estMOI38 to determine MOI for samples, 
and the major allele was used when heterozygous SNP calls were found.
Determining and excluding subtelomeric regions. To exclude hypervariable subtelomeric regions 
the P. malariae genome was split into 5 kb segments and the average number of SNPs was calculated. We defined 
an upper limit for the number of SNPs within each window in order to identify highly polymorphic windows. 
This SNP limit was used in conjunction with the positions of the Pm-fam gene families to define the subtelom-
eric regions of each chromosome and exclude these from downstream analysis.
Population genetics. To investigate the population structure of P. malariae parasites, a distance matrix 
was created which was based on a matrix of pairwise identity calculated from the SNPs present in each sample. 
Using the distance matrix, a maximum likelihood tree was produced using Iqtree39 with Modelfinder40 to select 
the best model of substitution and ultrafast bootstrap  analysis41. The resulting Newick tree was visualised in 
 iTOL42. The nucleotide diversity (π) metric was used to investigate the genetic variability between samples, and 
was calculated using the pegas (v0.10)  package58, which defines nucleotide diversity as the average number of 
SNPs per position between two sequences.
Drug resistance orthologs. Orthologs of known genes involved in drug resistance in P. falciparum were 
analysed. The SNPs were described using the snpEff  software59 which annotates the genes affected, the type of 
mutation, and if non-synonymous, the amino-acid change that has occurred. The coverage of genes of interest 
was also analysed using the output file from applying sambamba  software57. The genes investigated and their 
respective IDs are summarised in S5 Table.
Data availability
All raw sequence data is listed in the European Nucleotide Archive (study accession number PRJEB33837).
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